1. Alkrinawi J, Alnees M, Masu’d M, et
al. Phenotype-specific determinants
of health-related quality of life in
Crohn’s disease and ulcerative colitis:
a multicenter cross-sectional study.
BMC gastroenterology. 2026;26(1):97.
2. Singh S DP. Ulcerative colitis:
clinical manifestations and
management. . Yamada’s Textbook
of Gastroenterology2022. p. 1248-93.
3. Dolinger M, Torres J, Vermeire S.
Crohn’s disease. Lancet (London,
England). 2024;403(10432):1177-91.
4. Yewale RV, Ramakrishna BS,
Doraisamy BV, et al. Long-term safety
and effectiveness of azathioprine in the
management of inflammatory bowel
disease: A real-world experience.
JGH open : an open access journal
of gastroenterology and hepatology.
2023;7(9):599-609.
5. Raychaudhuri R, Lin DW,
Montgomery RB. Prostate Cancer: A
Review. Jama. 2025;333(16):1433-46.
6. Chen Z , Z hang E , L iu N , e t a l.
Relationship between infection or
inflammation of prostate and risk
of prostate cancer: a cross-sectional
population-based study. European
Journal of Medical Research.
2026;31(1):191.
7. Huang L, LaBonte MJ, Craig SG, et
al. Inflammation and Prostate Cancer:
A Multidisciplinary Approach
to Identifying Opportunities for
Treatment and Prevention. Cancers.
2022;14(6).
8. Radej S, Szewc M, Maciejewski
R. Prostate Infiltration by Treg and
Th17 Cells as an Immune Response
to Propionibacterium acnes Infection
in the Course of Benign Prostatic
Hyperplasia and Prostate Cancer.
International journal of molecular
sciences. 2022;23(16).
9. Liu D, Cao M, Wang H, et al.
Association between inflammatory
bowel disease and cancer risk:
evidence triangulation from genetic
correlation, Mendelian randomization,
and colocalization analyses across
East Asian and European populations.
BMC medicine. 2024;22(1):137.
10. Adebayo AS, Agbaje K, Adesina
SK, et al. Colorectal Cancer:
Disease Process, Current Treatment
Options, and Future Perspectives.
Pharmaceutics. 2023;15(11).
11. Zhou BG, Yu Q, Jiang X, et al.
Association between inflammatory
bowel disease and risk of incident
prostate cancer: a systematic review
and meta-analysis of cohort studies.
International Journal of Colorectal
Disease. 2023;38(1):168.
12. Desai AS, Sagar V, Lysy B, et al. Inflammatory bowel disease induces
inflammatory and pre-neoplastic
changes in the prostate. Prostate
cancer and prostatic diseases.
2022;25(3):463-71.
13. Heydari K, Rahnavard M, Ghahramani
S, et al. Global prevalence and
incidence of inflammatory bowel
disease: a systematic review and metaanalysis
of population-based studies.
Gastroenterology and hepatology
from bed to bench. 2025;18(2):132-46.
14. Rahmati L, Mooghali A, Kamani
SMH, et al. Economic Burden of
Inflammatory Bowel Disease in
Shiraz, Iran. Archives of Iranian
medicine. 2023;26(1):23-8.
15. Safarpour AR, Hosseini SV,
Mehrabani D. Epidemiology of
inflammatory bowel diseases in iran
and Asia; a mini review. Iranian
journal of medical sciences. 2013;38(2
Suppl):140-9.
16. Jarmakiewicz-Czaja S, Zielińska
M, Sokal A, et al. Genetic and
Epigenetic Etiology of Inflammatory
Bowel Disease: An Update. Genes.
2022;13(12).
17. Singh N, Ber nstein CN.
Environmental risk factors for
inflammatory bowel disease. United
European gastroenterology journal.
2022;10(10):1047-53.
18. Balestrieri P, Cicala M, Ribolsi
M. Psychological distress in
inflammatory bowel disease. Expert
review of gastroenterology &
hepatology. 2023;17(6):539-53.
19. Qi Y, Wu HM, Yang Z, et al.
New Insights into the Role of
Oral Microbiota Dysbiosis in the
Pathogenesis of Inflammatory Bowel
Disease. Digestive diseases and
sciences. 2022;67(1):42-55.
20. Wilson TK, Zishiri OT. Prostate
Cancer: A Review of Genetics,
Current Biomarkers and Personalised
Treatments. Cancer reports (Hoboken,
NJ). 2024;7(10):e70016.
21. Giona S. The Epidemiology of
Prostate Cancer. In: Bott SRJ, Ng KL,
editors. Prostate Cancer. Brisbane
(AU): Exon Publications Copyright:
The Authors.; 2021.
22. Sekhoacha M, Riet K, Motloung P, et
al. Prostate Cancer Review: Genetics,
Diagnosis, Treatment Options, and
Alternative Approaches. Molecules
(Basel, Switzerland). 2022;27(17).
23. Nowroozi MR FE, Hushmandi K,
Amini E, et al. Trends in Incidence
of Prostate Cancer in Iran and Its
31 Provinces During 2003 - 2016.
2023;16(1):e136819. doi: https://doi.
org/10.5812/ijcm-136819. Int J Cancer
Manag. 2023;16(1:e136819. ).
24. Charvat H, Matsuda T. Agestandardized
mortality-to-incidence
ratio for prostate cancer in the
world. Japanese Journal of Clinical
Oncology. 2025;55:1299-300.
25. Olakowski M, Bułdak Ł. Modifiable
and Non-Modifiable Risk Factors for
the Development of Non-Hereditary
Pancreatic Cancer. Medicina (Kaunas,
Lithuania). 2022;58(8).
26. Down L, Barlow M, Bailey SER, et al.
Association between patient ethnicity
and prostate cancer diagnosis
following a prostate-specific antigen
test: a cohort study of 730,000 men
in primary care in the UK. BMC
medicine. 2024;22(1):82.
27. Pejčić T, Zeković M, Bumbaširević
U, et al. The Role of Isoflavones in
the Prevention of Breast Cancer and
Prostate Cancer. Antioxidants (Basel,
Switzerland). 2023;12(2).
28. Giri VN, Beebe-Dimmer JL. Familial
prostate cancer. Seminars in oncology.
2016;43(5):560-5.
29. Ziglioli F, Patera A, Isgrò G, et al.
Impact of modifiable lifestyle risk
factors for prostate cancer prevention:
a review of the literature. Frontiers in
oncology. 2023;13:1203791.
30. Vitale E, Rizzo A, Halemani K, et
al. Normal Weight, Overweight
and Obesity Conditions Associated
to Prostate Neoplasm Stages-A
Systematic Review and Meta-
Analysis. Biomedicines. 2025;13(5).
31. Królikowska K, Kiślak J, Orywal K,
et al. Vitamins in the Pathogenesis
of Prostate Cancer: Implications for
Prevention and Therapeutic Support.
International journal of molecular
sciences. 2025;26(9).
32. Haddad A, Al-Sabbagh MQ, Al-Ani
H, et al. Inflammatory bowel disease
and prostate cancer risk: A systematic
review. Arab journal of urology.
2020;18(4):207-12.
33. Ge Y, Shi Q, Yao W, et al. The
association between inflammatory
bowel disease and prostate cancer risk:
a meta-analysis. Prostate cancer and
prostatic diseases. 2020;23(1):53-8.
34. Mukherjee T, Kumar N, Chawla M, et
al. The NF-κB signaling system in the
immunopathogenesis of inflammatory
bowel disease. Science signaling.
2024;17(818):eadh1641.
35. Cheng W, Liao Y, Mou R, et al.
Inflammatory bowel disease and
prostate cancer risk: a two-sample
Mendelian randomization analysis.
2023;Volume 14 - 2023.
36. He M-m, Lo C-H, Wang K, et
al. Immune-Mediated Diseases
Associated With Cancer Risks. JAMA
Oncology. 2022;8(2):209-19.
37. Zhong W, Wu K, Long Z, et al. Gut
dysbiosis promotes prostate cancer
progression and docetaxel resistance
via activating NF-κB-IL6-STAT3
axis. Microbiome. 2022;10(1):94.
38. Prakash P, Verma S, Gupta S. Influence
of microbiome in intraprostatic
inflammation and prostate cancer.
The Prostate. 2024;84(13):1179-88.
39. Dovey Z, Tomas Bort E, Mechanick
JI. Adipokine Metabolic Drivers,
Gut Dysbiosis, and the Prostate
Microbiome: Novel Pathway
Enrichment Analysis of the Adiposity-
Based Chronic Disease—Prostate
Cancer Network. 2026;18(2):206.
40. Frigerio S, Khan HN, Amini M,
et al. Spatial transcriptomics and
immunophenotyping uncover chronic
inf lammation-induced immune
adaptations favoring dysplasia
development in patients at risk of
colitis-associated cancer. Journal of
Crohn’s & colitis. 2025;19(10).
41. Pérez-Campos Mayoral E, Pérez-
Campos Mayoral L, Hernández-
Huerta MT, et al. Microbial Genomic
Consortia in Prostate Cancer:
Mechanistic Signaling, the Gut–
Prostate Axis, and Translational
Perspectives. 2026;18(8):1219.
42. Novysedlak R, Guney M, Al
Khouri M, et al. The Immune
Microenvironment in Prostate
Cancer: A Comprehensive Review.
Oncology. 2025;103(6):521-45.
43. Kura Y, De Velasco MA, Sakai K, et
al. Exploring the relationship between
ulcerative colitis, colorectal cancer,
and prostate cancer. Human cell.
2024;37(6):1706-18.
44. Cooke M, Elyoussef Y, Abba MC, et
al. Diacylglycerol-Regulated Protein
Kinases and Transcriptional Networks
in Prostate Cancer. Endocrinology.
2026;167(4).
45. Oseni SO, Naar C, Pavlović M,
et al. The Molecular Basis and
Clinical Consequences of Chronic
Inflammation in Prostatic Diseases:
Prostatitis, Benign Prostatic
Hyperplasia, and Prostate Cancer.
Cancers. 2023;15(12).
46. Jiang H. Prostate Cancer Bone
Metastasis: Molecular Mechanisms of
Tumor and Bone Microenvironment.
Cancer management and research.
2025;17:219-37.
47. Mao H, Zhao X, Sun S-c. NF-κB
in inf lammation and cancer. Cellular & Molecular Immunology.
2025;22(8):811-39.
48. Li C, Cheng D, Li P. Androgen
receptor dynamics in prostate cancer:
from disease progression to treatment
resistance. 2025;Volume 15 - 2025.
49. Hashemi M, Taheriazam A, Daneii P,
et al. Targeting PI3K/Akt signaling in
prostate cancer therapy. Journal of
cell communication and signaling.
2023;17(3):423-43.
50. Ichikawa T, Shimosaki S, Nakahata
S, et al. Clathrin-associated SCYL2
contributes to the activation of PI3K/
AKT signaling and tumorigenesis
through PTEN phosphorylation
in adult T-cell leukemia/
lymphoma. Cancer Gene Therapy.
2026;33(3):314-22.
51. Bergez-Hernández F, Irigoyen-
Arredondo M, Martínez-Camberos A.
A systematic review of mechanisms
of PTEN gene down-regulation
mediated by miRNA in prostate
cancer. Heliyon. 2024;10(15):e34950.
52. Alobid S. Targeting the PI3K/AKT/
mTOR signaling pathway in prostate
cancer: Molecular dysregulation,
therapeutic advances, and future
directions. Saudi pharmaceutical
journal : SPJ : the official publication
of the Saudi Pharmaceutical Society.
2026;34(1):2.
53. Hedin CRH, Sonkoly E, Eberhardson
M, et al. Inflammatory bowel disease
and psoriasis: modernizing the
multidisciplinary approach. Journal of
internal medicine. 2021;290(2):257-78.
54. Andrzejczak K, Kucharczyk E,
Sternak A, et al. Gut Dysbiosis and
the Molecular Landscape of the Gut–
Skin Axis: Comparative Insights
and Therapeutic Implications for
Atopic Dermatitis and Psoriasis.
2026;15(7):594.
55. Irrazabal T, Thakur BK, Croitoru K,
et al. Preventing Colitis-Associated
Colon Cancer With Antioxidants:
A Systematic Review. Cellular and
molecular gastroenterology and
hepatology. 2021;11(4):1177-97.
56. Romano L, Napolitano L, Crocetto
F, et al. Prostate and gut: Any
relationship? A narrative review
on the available evidence and
putative mechanisms. The Prostate.
2024;84(6):513-24.
57. Miyake M, Tatsumi Y, Ohnishi K, et
al. Prostate diseases and microbiome
in the prostate, gut, and urine. Prostate
international. 2022;10(2):96-107.
)